Can inflammation markers predict heart failure outcomes?
NCT ID NCT07320014
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study will enroll 112 adults hospitalized for heart failure with preserved or mildly reduced ejection fraction. Researchers will collect blood and urine samples to measure inflammatory biomarkers and analyze genetic factors. The goal is to identify markers that predict complications and guide personalized treatment. Participation does not change standard medical care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better predict which heart failure patients are at higher risk of complications, leading to more personalized care.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly change patient care. Results may not apply to all heart failure patients, and genetic findings may not be actionable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?
- Can shedding pounds reboot the Heart's exercise engine?